News
BioNxt fast-tracks US patent for multiple sclerosis drug and secures broad platform IP covering autoimmune neurology pipeline: Vancouver, BC Friday, August 22, 2025, 09:00 Hrs [IS ...
VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
The Company has formally initiated the prioritized examination process for its U.S. patent application for BNT23001, a novel sublingual thin-film cladribine formulation for multiple sclerosis (MS), ...
The Company has formally initiated the prioritized examination process for its U.S. patent application for BNT23001, a novel sublingual thin-film cladribine formulation for multiple sclerosis (MS ...
VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
The umbrella patent provides long-term exclusivity, extending into the 2040s, not only for cladribine, but for a broad class of drug compounds delivered via BioNxt's proprietary sublingual thin-film ...
The U.S. Food and Drug Administration has approved Tonmya (cyclobenzaprine hydrochloride) sublingual tablets for the treatment of fibromyalgia in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback